Lupus Anticoag Eval Reflx 7079

LUPA

LUPA

PTT-LA and dRVVT with Reflex Confirmations

1.5 mL frozen platelet-poor plasma (x2) collected in separate 3.2% sodium citrate (light blue-top) tubes

1

Draw 4 light blue and send plasma frozen

BLUE

F

Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 30 days

Hemolysis • Received thawed

Set up: Mon-Fri; Report available: 1-4 days

Expected impact by therapeutic levels (potential interference depends upon drug concentration): Warfarin: no effect (panel includes mixing studies which correct for Warfarin-induced factor deficiencies); Heparin (UFH or LMWH): possible to misclassify as LA; Dabigatran or Argatroban (Thrombin Inhibitors): panel includes Thrombin Time (TT) which detects thrombin inhibitors, unable to detect if TT significantly abnormal; Rivaroxaban or Apixaban (Factor Xa Inhibitors): possible to misclassify as LA.

Lupus anticoagulants (LA) are members of a family of antibodies with phospholipid-protein specificity. LA may be defined as an immunoglobulin, IgG or IgM or a mixture of both, that interferes with one or more of the in-vitro phospholipid (PL) dependent tests of coagulation. These antibodies are not associated with a hemorrhagic diathesis, but rather have been linked to thrombotic events. In addition to thrombosis other clinical complications have been associated with the presence of LA. These include strokes, nonbacterial thrombotic endocarditis, livedo reticularis and a variety of obstetrical complications such as intrauterine fetal death, recurrent spontaneous abortion, fetal growth retardation, early onset preeclampsia and chorea gravidarum.

⁠⁠⁠⁠⁠⁠⁠Note: Target specific anticoagulant therapy (anti-Xa medications, direct thrombin inhibitors) may cause false positive results.